

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Identification of a Core Outcome Set for Reporting Outcomes of Management of Velopharyngeal Dysfunction; The VPD-COS Initiative

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-036824
Article Type:	Protocol
Date Submitted by the Author:	06-Jan-2020
Complete List of Authors:	de Blacam, Catherine; Our Lady's Children's Hospital; Royal College of Surgeons in Ireland Baylis, Adriane; Nationwide Children's Hospital, Plastic and Reconstructive Surgery; Ohio State University College of Medicine Kirschner, Richard; Nationwide Children's Hospital, Plastic and Reconstructive Surgery; Ohio State University College of Medicine Smith, Susan; RCSI, General Practice Sell, Debbie; Great Ormond Street Hospital for Children Sie, Kathleen; Seattle Children's Hospital Harris, Helen Orr, David; Our Lady's Children's Hospital; Trinity College Dublin
Keywords:	Paediatric plastic & reconstructive surgery < PAEDIATRIC SURGERY, Speech pathology < OTOLARYNGOLOGY, Plastic & reconstructive surgery < SURGERY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**TITLE**

Identification of a Core Outcome Set for Reporting Outcomes of Management of Velopharyngeal Dysfunction; The VPD-COS Initiative

**CORRESPONDING AUTHOR**

Catherine de Blacam  
Dublin Cleft Centre  
Children's Health Ireland at Crumlin  
Cooley Road  
Dublin 12  
Ireland  
[catherinedeblacam@rcsi.ie](mailto:catherinedeblacam@rcsi.ie)  
+353 1 4096050

**CO-AUTHORS**

Adriane Baylis  
Plastic and Reconstructive Surgery  
Nationwide Children's Hospital and The Ohio State University College of Medicine,  
Columbus, Ohio, USA

Richard E. Kirschner  
Plastic and Reconstructive Surgery  
Nationwide Children's Hospital and The Ohio State University College of Medicine,  
Columbus, Ohio, USA

Susan Smith  
RCSI General Practice and HRB Centre for Primary Care Research  
Royal College of Surgeons in Ireland, Dublin, Ireland

Debbie Sell  
Speech and Language Therapy  
Great Ormond Street Hospital NHS Foundation Trust, London, UK

Kathleen C.Y. Sie  
Pediatric Otolaryngology  
Seattle Children's Hospital, Washington, USA

Helen E Harris  
London, UK

David JA Orr  
Dublin Cleft Centre  
Children's Health Ireland at Crumlin, Dublin, Ireland

**WORD COUNT**

2,629 words

**STUDY DATES**

September 2018 – September 2020

**ABSTRACT****Introduction**

Velopharyngeal dysfunction (VPD) is present in up to 40% of patients following cleft palate repair. Children with VPD display hypernasal speech, nasal air emission or turbulence, and other distortions of speech, and are at high risk for developing articulation disorders. The overall result is decreased intelligibility and acceptability of speech, as well as significant functional and social impairments. There are several surgical approaches for the management of children with VPD that can be broadly described as palatal, pharyngeal and palatopharyngeal procedures. However, standard treatment protocols for VPD have not been well defined. In a systematic review, the authors identified mainly retrospective case series, which described results of surgical interventions for VPD using diverse parameters, particularly with regard to perceptual speech assessment. There is a need for a core outcome set (COS) to reduce outcome reporting bias and heterogeneity across studies of VPD. The COS-VPD Initiative is an international effort to establish a COS for the reporting of studies of management of VPD.

**Methods and analysis**

The study will be carried out according to the guidance of the Core Outcome Measures in Effectiveness Trials (COMET) initiative. A long list of clinical and patient-reported outcomes will be identified from a systematic review of the literature. A two-stage Delphi consensus process will be used to refine this list in to a COS. An international panel of patients, parents and multidisciplinary clinical and academic experts will be invited to participate in this process.

**Ethics and dissemination**

The study has ethical approval through Our Lady's Children's Hospital Crumlin Dublin Research and Ethics Committee, Ref: GEN/683/18 and is registered with the Core Outcome Measures in Effectiveness Trials Initiative (<http://www.cometinitiative.org/studies/details/1146?result=true>). The COS will be published in the peer-reviewed literature, presented at international research meetings and distributed to patient-representative organizations.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- A core outcome set will reduce both outcome reporting bias and heterogeneity between studies, thus allowing meaningful collation of results across multiple institutions.
- The study achieves stakeholder engagement from multidisciplinary clinicians, patients and parents/ guardians.
- There is international expertise contributed by the study steering group.
- The core outcome set identified will be broadly applicable to case series, cohort studies, as well as randomized controlled trials.
- Further study will be required to identify outcome measurement instruments to assess the outcomes selected.

## INTRODUCTION

The velopharyngeal valve is made up of the soft palate, the palatopharyngeus muscle and the superior pharyngeal constrictor muscle. It is critically important during speech because it controls the degree and balance of sound energy and airflow into the oral versus nasal part of the vocal tract. Velopharyngeal dysfunction (VPD) refers to inadequate closure of the velopharyngeal sphincter during speech, resulting in hypernasal resonance, nasal emission of air and decreased intraoral pressure for oral pressure consonants. A child with VPD, unable to easily produce oral consonants, may develop articulation disorders, including maladaptive compensatory articulations such as glottal stops and pharyngeal fricatives.[1] The overall result is decreased intelligibility of speech and functional and social impairment. [2]

The velopharyngeal valve may fail for structural reasons such as overt or submucous cleft palate or a repaired cleft palate that remains short or insufficiently mobile due to deficiency of palatal tissue, surgical scarring and/or abnormally positioned palatal muscles. VPD is present in up to 40% of patients following cleft palate repair.[3-5] Neuromuscular disorders such as stroke, cerebral palsy, myopathy or neuropathy may also result in failure of closure of a structurally normal velopharyngeal sphincter.[6-8] While speech therapy may help to correct articulation errors secondary to VPD, correction of a structurally or neuromuscularly incompetent velopharyngeal port requires a physical intervention, most commonly surgery.

The aim of surgical intervention in VPD is to create a functional seal between the nasopharynx and the oropharynx during speech production, whilst avoiding nasal obstruction but maintaining a nasal airway. Surgical interventions can be divided into three broad categories: palatal procedures, pharyngeal procedures and palatopharyngeal procedures. Palatal procedures involve reorientating malpositioned palate muscles by carrying out a secondary intravelar veloplasty,[9 10] or a Furlow double opposing z-plasty.[11-14] Alternatively, extra tissue can be introduced into the palate in the form of buccal myomucosal flaps raised from the inner aspect of the cheek.[15-17] Pharyngeal procedures comprise circular pharyngoplasties and posterior pharyngeal wall augmentation. Hynes described the first circular pharyngoplasty, which uses musculomucosal flaps based on the salpingopharyngeus muscle placed high in the nasopharynx to create a static constriction.[18] Several variations of circular pharyngoplasty have subsequently been described.[19-21] The posterior pharyngeal wall can be augmented using autologous fat or material implants.[22 23] Finally, a palatopharyngeal flap procedure consists of raising a flap of mucosa and superior pharyngeal constrictor muscle from the posterior pharyngeal wall and suturing it into the nasal layer of the soft palate.[24-26]

The recording of outcomes of surgery has become standardized in many centres with the advent of programmes such as the American College of Surgeons National Surgical Quality Improvement Programme (ACS-NSQIP) in the United States,[27] or the Dutch nationwide

1  
2  
3  
4 routine reporting programme.[28] Outcomes such as bleeding or infection, as well as  
5 unplanned ICU admission and patient length of stay are routinely included in these large-  
6 scale datasets. More specific outcomes relevant to subspecialty procedures such and cleft and  
7 speech surgery will not be captured however. In addition to the speech outcome, a particular  
8 concern in surgery for VPD is the impact of the procedure on the nasal airway. Surgical  
9 procedures carried out on the velopharyngeal sphincter with the aim of correcting nasal  
10 escape of air during speech may result in obstructed airflow during sleep. Sleep-disordered  
11 breathing (SDB) is an umbrella term for several chronic conditions in which partial or  
12 complete cessation of breathing occurs many times throughout the night. Symptoms may  
13 include snoring, pauses in breathing and disturbed sleep. The result is daytime fatigue that  
14 interferes with a person's ability to function and reduces quality of life. Therefore, in  
15 addition to standard surgical outcomes, it is crucial to screen for SDB and record it as an  
16 outcome following surgery for VPD.  
17  
18  
19  
20  
21

22 As outlined, the surgical options in the management of VPD are numerous, and the literature  
23 lacks prospective comparative series. We recently carried out a systematic review of the  
24 literature up to 2015 (including randomized controlled trials, cohort studies and case series).  
25 [29] Eighty-three studies satisfied the inclusion criteria, comprising data on 4,011 patients.  
26 Overall, 70.7% of patients attained normal resonance and 65.3% attained resolution of  
27 abnormal nasal emission following surgical intervention. There was no notable difference in  
28 speech outcomes, need for further surgery or occurrence of sleep disordered breathing across  
29 the categories of surgery examined. However, it was noted that outcomes were recorded  
30 using diverse parameters, particularly with regard to perceptual speech assessment, often  
31 with weak speech methodologies. This made comparison, even of well-defined cohort  
32 studies, problematic and meant that the clinical application potential of the review was  
33 limited.  
34  
35  
36  
37  
38

39 In this context, one might assume that randomized controlled trials comparing different types  
40 of VPD surgery would emerge as the preferred study design. However, there are practical  
41 difficulties in achieving this because of the relatively small numbers of patients with VPD,  
42 their heterogeneity and the existence of well-established protocols in individual units.  
43 Therefore comparative, cross-centre cohort studies are likely to continue to be important in  
44 research into VPD surgery. In order to usefully inform clinical decision-making, it is  
45 essential that the results of such studies can be compared in a standardized way.  
46  
47  
48  
49

50 One method to achieve this is to develop a core outcome set (COS). A core outcome set is a  
51 minimum set of outcomes that should be measured and reported in all studies in a specific  
52 field. Core outcome sets have been demonstrated to improve outcome reporting in healthcare  
53 trials.[30] It is important to note that a COS represents a minimum set of relevant outcomes  
54 that should be measured in a clinical study of a particular condition. The intent is not to limit  
55 researchers but rather to provide them with a minimum list of outcomes to include in their  
56  
57  
58  
59



1  
2  
3  
4 studies along with others of their choosing. There is a precedent for COS development in  
5 cleft care. The MOMENT study, published in 2015, developed a COS for the reporting of  
6 effectiveness trials for the management of otitis media with effusion (OME) in children with  
7 cleft palate.[31] A COS reflecting the opinions of clinicians and parents was developed,  
8 which included nine core outcomes that can be used in future trials of the management of  
9 OME in patients with clefts.  
10  
11

12  
13 The aim of the current study is to develop a COS for consistent reporting of outcomes in  
14 studies of management of VPD. There is currently no available COS for studies of patients  
15 with VPD (<http://www.comet-initiative.org/studies/search>). Developing a COS would reduce  
16 outcome reporting bias and heterogeneity across studies of VPD. This would allow  
17 meaningful collation and comparison of results between different aetiologies, surgical  
18 protocols and institutions. Such an instrument would strengthen evidence for clinical  
19 decision making regarding intervention selection and would ultimately improve care for  
20 patients with VPD.  
21  
22  
23  
24  
25

## 26 **METHODS AND ANALYSIS**

27 The study will be carried out according to the guidance of the Core Outcome Measures in  
28 Effectiveness Trials (COMET) initiative.[32]  
29  
30

### 31 **Steering group**

32 A steering group will oversee the development of the core outcome set. The steering group  
33 consists of academic cleft surgeons (CdeB, REK, KCYS and DJAO) and speech and  
34 language therapists (AB and DS), an expert in COS development (SS) and the parent of a  
35 patient with VPD (HH). All members of the steering group will be co-authors of the COS.  
36  
37  
38

### 39 **Public and patient involvement**

40 The parent of a patient with VPD is included in the steering group of the study and in the  
41 authorship of this paper. Knowledge of the patient experience of VPD has been provided  
42 throughout the development of the protocol.  
43  
44  
45

### 46 **Objectives**

- 47 1. Compile a comprehensive list of clinical and patient-reported outcomes based on review  
48 of the published literature.
- 49 2. Group the listed outcomes in to predefined themes.
- 50 3. Achieve consensus on a minimum set of relevant outcomes for reporting studies of  
51 interventions for VPD.  
52  
53  
54

### 55 **Identification and grouping of outcomes for the consensus process**

56  
57  
58  
59  
60

1  
2  
3  
4 A systematic review of 83 papers, which presented results of surgery for VPD, has been  
5 published.[29] Outcomes recorded in papers included in this systematic review have been  
6 identified and recorded by the steering group. These outcomes have been presented and  
7 discussed at the Craniofacial Society of Great Britain and Ireland annual meeting  
8 (Birmingham UK 2018) and the Second International Symposium on VPD (Columbus Ohio  
9 USA 2018). Both of these meetings provided the opportunity to receive contributions from a  
10 wide range of multidisciplinary experts in the field through a series of focused workshops.  
11 Participants in these workshops were asked to review outcomes relevant to their clinical field  
12 and to comment on the suitability of inclusion of the outcome in the core outcome set. Based  
13 on this discussion, further outcomes were added to the initial list derived from the systematic  
14 review. This long list of outcomes will be reviewed and categorized independently by each  
15 member of the steering group into the following pre-specified themes: patient-reported  
16 outcomes; speech outcomes; nasal airway outcomes (including sleep-disordered breathing);  
17 surgical care outcomes.  
18  
19  
20  
21  
22  
23

### 24 **Delphi process**

25 A Delphi process will be carried out amongst international clinical cleft teams and their  
26 patients/parents to achieve consensus on the outcomes to be included in the COS. The Delphi  
27 process is a commonly used consensus technique,[33] which has frequently been used in  
28 COS development.[34-37] The Delphi process ensures that anonymous opinions can be  
29 obtained in a way that gives equal influence to all who participate, and avoids an individual  
30 participant being influenced by the opinions of any other participant.  
31  
32  
33

34 Plain language documents, which have been developed by the COMET initiative, will be  
35 used to explain COS development methodology to participants. The language of the  
36 outcomes themselves will be clarified and plain-language definitions will be added where  
37 necessary. The same version of the questionnaire will be used for both clinical and  
38 patient/parent participants. The questionnaire will be pilot tested to assess usability by  
39 members of staff and patient representatives in the departments of the steering group and  
40 modified accordingly.  
41  
42  
43  
44

45 There is no robust method for calculating the required sample size for a Delphi survey and  
46 assumptions are based on COMET Initiative guidelines and previous studies.[32] A balanced  
47 mix of stakeholders (adult patients, parents, cleft surgeons, speech and language therapists  
48 and cleft nurse specialists) will be identified by purposive sampling by the steering group,  
49 aiming for a total of 30 participants in the Delphi panel. Clinicians will only be invited to  
50 participate if they are involved in the clinical care of children with VPD. International  
51 experts in the field will be identified based on their interest in VPD surgical management and  
52 research. While the steering group is made up of Irish, UK and USA participants, the aim is  
53 to include a wider international representation in the Delphi panel, including representation  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from low and middle-income countries. In keeping with previously described methodology,  
5 adult patient and parent participants will comprise 20% of the Delphi panel.[38]  
6

7  
8 Research Electronic Data Capture (REDCap) software will be used to deliver the Delphi  
9 survey to all participants.[39] Potential participants will be emailed and asked for their  
10 consent to participate in the Delphi panel. Having received their consent, they will then be  
11 invited to complete an online Delphi questionnaire via an embedded link in a subsequent  
12 email. The panel will answer questionnaires in two rounds. After each round, the steering  
13 group will provide a de-identified summary of the panel's answers from the previous round.  
14 Thus, participants are encouraged to revise their earlier answers in light of the responses of  
15 other members of their panel. Participants will be asked to complete each round of the  
16 Delphi exercise within three weeks of receipt of the email and will be reminded of this at the  
17 start of each survey. A reminder email will be sent at the end of week two to prompt  
18 completion of the survey. One further reminder will be sent to non-responders at the end of  
19 the three-week period.  
20  
21  
22  
23

24  
25 At the beginning of the first (Round 1) survey, participants will be presented with some plain  
26 language introductory information detailing the purpose and design of the study, as well as a  
27 glossary of terms. Round 1 content will comprise a long list of outcomes to be scored.  
28 Participants will also be provided with an option to add additional outcomes that they think  
29 are relevant. Any new outcomes identified by at least two Delphi participants will be  
30 included in Round 2 of the process. Participants will be asked to score each of the outcomes  
31 listed in Round 1 using the Grading of Recommendations, Assessment, Development and  
32 Evaluations (GRADE) scale of 1 to 9, with 1 to 3 labeled 'not important', 4 to 6 labeled  
33 'important but not critical' and 7 to 9 labeled 'critical'. [40]  
34  
35  
36  
37

38 Round 1 responses will be analyzed according to the number of participants scoring each  
39 outcome within the GRADE criteria (1–3, 4–6, 7–9) for the purpose of group feedback in  
40 Round 2. Consensus criteria will be specified a priori. Any outcome with a rating of 7 to 9 by  
41 70% or more of the panel *and* 1 to 3 by 15% or fewer will be included in the COS. Any  
42 outcome with a rating of 1 to 3 by 70% or more of the panel *and* 7 to 9 by 15% or fewer will  
43 be excluded.[41] All other combinations indicated that no consensus had been achieved for  
44 the outcome.  
45  
46  
47

48 Those who have not taken part in round 1 will not be invited to participate in round 2. Round  
49 2 will also be presented online and distributed via an electronic link embedded in an email.  
50 Round 2 will consist of all outcomes from Round 1 plus additional outcomes suggested by at  
51 least two Delphi participants in Round 1. In Round 2, participants will be shown their  
52 previous individual scores, together with group feedback (median score of group per item),  
53 and asked to reconsider their own scores in light of the group response when scoring  
54 outcomes in Round 2. Round 2 may be analyzed using more stringent criteria if a higher  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 proportion of outcomes than expected are rated critical. Specifically, a higher threshold of  
5 75% or more of the panel rating 7 to 9 and 25% or fewer rating 1 to 3 will be applied. This  
6 decision will be based on the steering group's judgement and giving due consideration to  
7 current COMET recommendations regarding outcomes.[32] All items retained after two  
8 rounds of the Delphi survey will be included in the final core outcome set.  
9  
10

## 11 12 13 **ETHICS AND DISSEMINATION**

14 The study has ethical approval through Our Lady's Children's Hospital Crumlin Dublin  
15 Research and Ethics Committee, Ref: GEN/683/18 and is registered with the Core Outcome  
16 Measures in Effectiveness Trials Initiative  
17 (<http://www.cometinitiative.org/studies/details/1146?result=true>).  
18  
19

20  
21 The Core Outcome Set-STAndards for Reporting (COS- STAR) Equator Network guidelines  
22 will be used for the reporting of the COS.[42] All members of the steering group will  
23 coauthor the final paper, which will be submitted for peer-review and publication in a journal  
24 of interest to the multidisciplinary cleft palate community. In order to reach as wide an  
25 audience as possible, the core outcome set will also be submitted for presentation at a  
26 number of international meetings, including the Craniofacial Society of Great Britain and  
27 Ireland, the American Cleft Palate Association and the International Symposium on VPD.  
28 The core outcome set will be distributed to patients and parents via patient representative  
29 groups.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Kummer A. Resonance Disorders and Velopharyngeal Dysfunction (VPD). In: Kummer A, ed. *Cleft Palate and Craniofacial Anomalies: Effects on Speech and Resonance*. 3rd ed. NY, USA: Delamar 2014:182-224.
2. Bhuskute A, Skirko JR, Roth C, et al. Association of Velopharyngeal Insufficiency With Quality of Life and Patient-Reported Outcomes After Speech Surgery. *JAMA facial plastic surgery* 2017;19(5):406-12. doi: 10.1001/jamafacial.2017.0639 [published Online First: 2017/07/21]
3. Sell D, Grunwell P, Mildinhall S, et al. Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. *Cleft Palate Craniofac J* 2001;38(1):30-7. doi: 10.1597/1545-1569\_2001\_038\_0030\_clapci\_2.0.co\_2
4. Cable BB, Canady JW, Karnell MP, et al. Pharyngeal flap surgery: long-term outcomes at the University of Iowa. *Plast Reconstr Surg* 2004;113(2):475-8. doi: 10.1097/01.PRS.0000100806.45065.35
5. Britton L, Albery L, Bowden M, et al. A cross-sectional cohort study of speech in five-year-olds with cleft palate +/- lip to support development of national audit standards: benchmarking speech standards in the United Kingdom. *Cleft Palate Craniofac J* 2014;51(4):431-51. doi: 10.1597/13-121
6. Hardy JC, Netsell R, Schweiger JW, et al. Management of velopharyngeal dysfunction in cerebral palsy. *The Journal of speech and hearing disorders* 1969;34(2):123-37. [published Online First: 1969/05/01]
7. Hillarp B, Ekberg O, Jacobsson S, et al. Myotonic dystrophy revealed at videoradiography of deglutition and speech in adult patients with velopharyngeal insufficiency: presentation of four cases. *Cleft Palate Craniofac J* 1994;31(2):125-33. doi: 10.1597/1545-1569(1994)031<0125:mdravo>2.3.co;2 [published Online First: 1994/03/01]
8. Horton SK, Murdoch BE, Theodoros DG, et al. Motor speech impairment in a case of childhood basilar artery stroke: treatment directions derived from physiological and perceptual assessment. *Pediatric rehabilitation* 1997;1(3):163-77. [published Online First: 1997/07/01]
9. Huang MH, Lee ST, Rajendran K. Anatomic basis of cleft palate and velopharyngeal surgery: implications from a fresh cadaveric study. *Plast Reconstr Surg* 1998;101(3):613-27; discussion 28-9. [published Online First: 1998/03/21]
10. Sommerlad BC, Mehendale FV, Birch MJ, et al. Palate re-repair revisited. *Cleft Palate Craniofac J* 2002;39(3):295-307. doi: 10.1597/1545-1569(2002)039<0295:prrr>2.0.co;2 [published Online First: 2002/05/23]
11. Furlow LT, Jr. Cleft palate repair by double opposing Z-plasty. *Plast Reconstr Surg* 1986;78(6):724-38. [published Online First: 1986/12/01]
12. Hudson DA, Grobbelaar AO, Fernandes DB, et al. Treatment of velopharyngeal incompetence by the Furlow Z-plasty. *Ann Plast Surg* 1995;34(1):23-6. [published Online First: 1995/01/01]
13. Chen PKT, Wu JTH, Chen YR, et al. Correction of secondary velopharyngeal insufficiency in cleft palate patients with the Furlow palatoplasty. *Plast Reconstr Surg* 1994;94(7):933-43.



14. Chen PK, Wu JT, Chen YR, et al. Correction of secondary velopharyngeal insufficiency in cleft palate patients with the Furlow palatoplasty. *Plast Reconstr Surg* 1994;94(7):933-41; discussion 42-3.
15. Hill C, Hayden C, Riaz M, et al. Buccinator sandwich pushback: A new technique for treatment of secondary velopharyngeal incompetence. *The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association* 2004;41(3):230-37.
16. Mann RJ, Neaman KC, Armstrong SD, et al. The double-opposing buccal flap procedure for palatal lengthening. *Plast Reconstr Surg* 2011;127(6):2413-18.
17. Hens G, Sell D, Pinkstone M, et al. Palate lengthening by buccinator myomucosal flaps for velopharyngeal insufficiency. *Cleft Palate Craniofac J* 2013;50(5):e84-91. doi: 10.1597/11-211
18. Hynes W. Pharyngoplasty by muscle transplantation. *Br J Plast Surg* 1950;3(2):128-35.
19. Orticochea M. A review of 236 cleft palate patients treated with dynamic muscle sphincter. *Plast Reconstr Surg* 1983;71(2):180-8. [published Online First: 1983/02/01]
20. Jackson IT. Sphincter pharyngoplasty. *Clin Plast Surg* 1985;12(4):711-7. [published Online First: 1985/10/01]
21. Sloan GM. Posterior pharyngeal flap and sphincter pharyngoplasty: the state of the art. *Cleft Palate Craniofac J* 2000;37(2):112-22. doi: 10.1597/1545-1569(2000)037<0112:PPFASP>2.3.CO;2
22. Filip C, Matzen M, Aagaens I, et al. Autologous fat transplantation to the velopharynx for treating persistent velopharyngeal insufficiency of mild degree secondary to overt or submucous cleft palate. *J Plast Reconstr Aesthet Surg* 2013;66(3):337-44. doi: 10.1016/j.bjps.2012.11.006
23. Gray SD, Pinborough-zimmerman J, Catten M. Posterior wall augmentation for treatment of velopharyngeal insufficiency. *Otolaryngol Head Neck Surg* 1999;121(1):107-12. doi: 10.1016/s0194-5998(99)70135-x [published Online First: 1999/07/02]
24. Skoog T. The Pharyngeal Flap Operation in Cleft Palate. A Clinical Study of Eighty-Two Cases. *Br J Plast Surg* 1965;18:265-82.
25. Honig CA. The treatment of velopharyngeal insufficiency after palatal repair. *Arch Chir Neerlandicum* 1967;19(1):71-81.
26. Honig CA. The treatment of velopharyngeal insufficiency after palatal repair. *Arch Chir Neerl* 1967;19(1):71-81. [published Online First: 1967/01/01]
27. Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. *Annals of surgery* 1998;228(4):491-507. [published Online First: 1998/10/28]
28. Marang-van de Mheen PJ, Stadlander MC, Kievit J. Adverse outcomes in surgical patients: implementation of a nationwide reporting system. *Qual Saf Health Care* 2006;15(5):320-4. doi: 10.1136/qshc.2005.016220 [published Online First: 2006/11/01]
29. de Blacam C, Smith S, Orr D. Surgery for Velopharyngeal Dysfunction: A Systematic Review of Interventions and Outcomes. *Cleft Palate Craniofac J* 2018;55(3):405-22. doi: 10.1177/1055665617735102

- 1
- 2
- 3
- 4 30. Kirkham JJ, Boers M, Tugwell P, et al. Outcome measures in rheumatoid arthritis
- 5 randomised trials over the last 50 years. *Trials* 2013;14:324. doi: 10.1186/1745-6215-
- 6 14-324 [published Online First: 2013/10/10]
- 7
- 8 31. Bruce I, Harman N, Williamson P, et al. The management of Otitis Media with Effusion
- 9 in children with cleft palate (mOMent): a feasibility study and economic evaluation.
- 10 *Health Technol Assess* 2015;19(68):1-374. doi: 10.3310/hta19680
- 11
- 12 32. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0.
- 13 *Trials* 2017;18(Suppl 3):280. doi: 10.1186/s13063-017-1978-4
- 14
- 15 33. Brown BB. Delphi Process: A Methodology Used for the Elicitation of Opinions of
- 16 Experts. Santa Monica, CA: RAND Corporation 1968.
- 17
- 18 34. Prinsen CA, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials
- 19 (COMET) initiative: protocol for an international Delphi study to achieve consensus
- 20 on how to select outcome measurement instruments for outcomes included in a 'core
- 21 outcome set'. *Trials* 2014;15:247. doi: 10.1186/1745-6215-15-247 [published Online
- 22 First: 2014/06/26]
- 23
- 24 35. Iyengar S, Williamson PR, Schmitt J, et al. Development of a core outcome set for
- 25 clinical trials in rosacea: study protocol for a systematic review of the literature and
- 26 identification of a core outcome set using a Delphi survey. *Trials* 2016;17(1):429.
- 27 doi: 10.1186/s13063-016-1554-3 [published Online First: 2016/09/02]
- 28
- 29 36. Harman NL, Bruce IA, Callery P, et al. MOMENT--Management of Otitis Media with
- 30 Effusion in Cleft Palate: protocol for a systematic review of the literature and
- 31 identification of a core outcome set using a Delphi survey. *Trials* 2013;14:70. doi:
- 32 10.1186/1745-6215-14-70 [published Online First: 2013/03/19]
- 33
- 34 37. Young A, Brookes S, Rumsey N, et al. Agreement on what to measure in randomised
- 35 controlled trials in burn care: study protocol for the development of a core outcome
- 36 set. *BMJ Open* 2017;7(6):e017267. doi: 10.1136/bmjopen-2017-017267 [published
- 37 Online First: 2017/07/04]
- 38
- 39 38. Smith SM, Wallace E, Salisbury C, et al. A Core Outcome Set for Multimorbidity
- 40 Research (COSmm). *Annals of family medicine* 2018;16(2):132-38. doi:
- 41 10.1370/afm.2178 [published Online First: 2018/03/14]
- 42
- 43 39. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a
- 44 metadata-driven methodology and workflow process for providing translational
- 45 research informatics support. *J Biomed Inform* 2009;42(2):377-81. doi:
- 46 10.1016/j.jbi.2008.08.010 [published Online First: 2008/10/22]
- 47
- 48 40. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and
- 49 deciding on important outcomes. *J Clin Epidemiol* 2011;64(4):395-400. doi:
- 50 10.1016/j.jclinepi.2010.09.012
- 51
- 52 41. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for
- 53 clinical trials: issues to consider. *Trials* 2012;13:132. doi: 10.1186/1745-6215-13-132
- 54
- 55 42. Kirkham JJ, Gorst S, Altman DG, et al. Core Outcome Set-STAndards for Reporting:
- 56 The COS-STAR Statement. *PLoS Med* 2016;13(10):e1002148. doi:
- 57 10.1371/journal.pmed.1002148
- 58
- 59
- 60

## CONTRIBUTORS

CdeB wrote the paper and conceived the project with the support of DJAO. HH contributed knowledge of the patient experience of VPD. SS contributed knowledge of core outcome set development. AB and DS contributed knowledge of speech and language therapy. REK, DJAO and KCYS contributed knowledge of VPD surgery and airway. All authors edited and critically revised the study protocol. All authors have read, contributed to and approved the manuscript.

## FUNDING STATEMENT

This study has not received any funding.

## COMPETING INTERESTS STATEMENT

The authors have no competing interests to declare.

## ETHICS APPROVAL

Our Lady's Children's Hospital Crumlin Dublin Research and Ethics Committee, Ref: GEN/683/18

## WORD COUNT

2,629 words



# BMJ Open

## Protocol for the Development of a Core Outcome Set for Reporting Outcomes of Management of Velopharyngeal Dysfunction.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-036824.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Apr-2020
Complete List of Authors:	de Blacam, Catherine; Our Lady's Children's Hospital; Royal College of Surgeons in Ireland Baylis, Adriane; Nationwide Children's Hospital, Plastic and Reconstructive Surgery; Ohio State University College of Medicine Kirschner, Richard; Nationwide Children's Hospital, Plastic and Reconstructive Surgery; Ohio State University College of Medicine Smith, Susan; RCSI, General Practice Sell, Debbie; Great Ormond Street Hospital for Children Sie, Kathleen; Seattle Children's Hospital Harris, Helen Orr, David; Our Lady's Children's Hospital; Trinity College Dublin
<b>Primary Subject Heading</b>:	Surgery
Secondary Subject Heading:	Paediatrics
Keywords:	Paediatric plastic & reconstructive surgery < PAEDIATRIC SURGERY, Speech pathology < OTOLARYNGOLOGY, Plastic & reconstructive surgery < SURGERY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**TITLE**

Protocol for the Development of a Core Outcome Set for Reporting Outcomes of Management of Velopharyngeal Dysfunction.

**CORRESPONDING AUTHOR**

Catherine de Blacam  
Dublin Cleft Centre  
Children's Health Ireland at Crumlin  
Cooley Road  
Dublin 12  
Ireland  
[catherinedeblacam@rcsi.ie](mailto:catherinedeblacam@rcsi.ie)  
+353 1 4096050

**CO-AUTHORS**

Adriane Baylis  
Plastic and Reconstructive Surgery  
Nationwide Children's Hospital and The Ohio State University College of Medicine,  
Columbus, Ohio, USA

Richard E. Kirschner  
Plastic and Reconstructive Surgery  
Nationwide Children's Hospital and The Ohio State University College of Medicine,  
Columbus, Ohio, USA

Susan Smith  
RCSI General Practice and HRB Centre for Primary Care Research  
Royal College of Surgeons in Ireland, Dublin, Ireland

Debbie Sell  
Speech and Language Therapy  
Great Ormond Street Hospital NHS Foundation Trust, London, UK

Kathleen C.Y. Sie  
Pediatric Otolaryngology  
Seattle Children's Hospital, Washington, USA

Helen E Harris  
London, UK

David JA Orr

Dublin Cleft Centre  
Children's Health Ireland at Crumlin, Dublin, Ireland

## WORD COUNT

3,471 words

## STUDY DATES

September 2018 – September 2020

## ABSTRACT

### Introduction

Velopharyngeal dysfunction (VPD) is present in up to 40% of patients following cleft palate repair. Children with VPD display hypernasal speech, nasal air emission and are at high risk for developing articulation disorders. The overall result is decreased intelligibility and acceptability of speech, as well as significant functional and social impairments. While there are several surgical approaches for the management of children with VPD, standard treatment protocols have not been well defined. There is a need for a core outcome set (COS) to reduce outcome reporting bias and heterogeneity across studies of VPD. The COS-VPD Initiative is an international effort to establish a COS for the reporting of studies of management of VPD.

### Methods and analysis

The study has been developed according to the Core Outcome Set-STANDARDS for Development (COS-STAD) standards for the design of a COS study and will be carried out according to the guidance of the Core Outcome Measures in Effectiveness Trials (COMET) initiative. A long list of clinical and patient-reported outcomes will be identified from a systematic review of the literature. A two-stage Delphi consensus process will be used to refine this list into a COS. An international panel of key stakeholders including patients, parents and multidisciplinary clinical and academic experts will be invited to participate in this process. Consensus criteria will be specified a priori and the steering group will ratify the final COS.

### Ethics and dissemination

The study has ethical approval through Children's Health Ireland at Crumlin Research and Ethics Committee, Ref: GEN/683/18. The study is registered with the COMET Initiative (<http://www.cometinitiative.org/studies/details/1146?result=true>). The COS will be disseminated by publication in the peer-reviewed literature, presentation at international research meetings and distribution to patient-representative organizations. This will facilitate application of the COS in future studies of the management of VPD.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- A core outcome set will reduce both outcome reporting bias and heterogeneity between studies, thus allowing meaningful collation of results across multiple institutions.
- The study achieves stakeholder engagement from multidisciplinary clinicians, patients and parents/ guardians.
- There is international expertise contributed by the study steering group.
- The core outcome set identified will be broadly applicable to case series, cohort studies, as well as randomized controlled trials.
- Further study will be required to identify outcome measurement instruments to assess the outcomes selected.

## INTRODUCTION

### Background

The velopharyngeal valve is made up of the soft palate, the palatopharyngeus muscle and the superior pharyngeal constrictor muscle. It is critically important during speech because it controls the degree and balance of sound energy and airflow into the oral versus nasal part of the vocal tract. Velopharyngeal dysfunction (VPD) refers to inadequate closure of the velopharyngeal sphincter during speech, resulting in hypernasal resonance, nasal emission of air and decreased intraoral pressure for oral pressure consonants. A patient with VPD, unable to easily produce oral consonants, may develop an articulation disorder, including maladaptive compensatory articulations such as glottal stops and pharyngeal fricatives.[1] The overall result is decreased intelligibility of speech and functional and social impairment. [2]

The velopharyngeal valve may fail for structural reasons such as overt or submucous cleft palate or a repaired cleft palate that remains short or insufficiently mobile due to deficiency of palatal tissue, surgical scarring and/or abnormally positioned palatal muscles. VPD is present in up to 40% of patients following cleft palate repair.[3-5] Neuromuscular disorders such as stroke, cerebral palsy, myopathy or neuropathy may also result in failure of closure of a structurally normal velopharyngeal sphincter.[6-8] While speech therapy may help to correct articulation errors secondary to VPD, correction of a structurally or neuromuscularly incompetent velopharyngeal port requires a physical intervention, most commonly surgery.

The aim of surgical intervention in VPD is to create a functional seal between the nasopharynx and the oropharynx during speech production, whilst avoiding nasal obstruction but maintaining a nasal airway. Surgical interventions can be divided into three broad categories: palatal procedures, pharyngeal procedures and palatopharyngeal procedures. Palatal procedures involve reorientating malpositioned palate muscles by carrying out a secondary intravelar veloplasty,[9 10] or a Furlow double opposing z-plasty.[11-14] Alternatively, extra tissue can be introduced in to the palate in the form of buccal myomucosal flaps raised from the inner aspect of the cheek.[15-17] Pharyngeal procedures comprise circular pharyngoplasties and posterior pharyngeal wall augmentation. Hynes described the first circular pharyngoplasty, which uses musculomucosal flaps based on the salpingopharyngeus muscle placed high in the nasopharynx to create a static constriction.[18] Several variations of circular pharyngoplasty have subsequently been described.[19-21] The posterior pharyngeal wall can be augmented using autologous fat or material implants.[22 23] Finally, a palatopharyngeal flap procedure consists of raising a flap of mucosa and superior pharyngeal constrictor muscle from the posterior pharyngeal wall and suturing it into the nasal layer of the soft palate.[24-26]

1  
2  
3  
4 The recording of outcomes of surgery has become standardized in many centres with the  
5 advent of programmes such as the American College of Surgeons National Surgical Quality  
6 Improvement Programme (ACS-NSQIP) in the United States,[27] or the Dutch nationwide  
7 routine reporting programme.[28] Outcomes such as bleeding or infection, as well as  
8 unplanned ICU admission and patient length of stay are routinely included in these large-  
9 scale datasets. More specific outcomes relevant to subspecialty procedures such as cleft and  
10 speech surgery will not be captured however. In addition to the speech outcome, a particular  
11 concern in surgery for VPD is the impact of the procedure on the nasal airway. Surgical  
12 procedures carried out on the velopharyngeal sphincter with the aim of correcting nasal  
13 escape of air during speech may result in obstructed airflow during sleep. Sleep-disordered  
14 breathing (SDB) is an umbrella term for several chronic conditions in which partial or  
15 complete cessation of breathing occurs many times throughout the night. Symptoms may  
16 include snoring, pauses in breathing and disturbed sleep. The result is daytime fatigue that  
17 interferes with a person's ability to function and reduces quality of life. Therefore, in  
18 addition to standard surgical outcomes, it is crucial to screen for SDB and record it as an  
19 outcome following surgery for VPD.  
20  
21  
22  
23  
24  
25

26 As outlined, the surgical options in the management of VPD are numerous, and the literature  
27 lacks prospective comparative series. We recently carried out a systematic review of the  
28 literature up to 2015 (including randomized controlled trials, cohort studies and case series).  
29 [29] Eighty-three studies satisfied the inclusion criteria, comprising data on 4,011 patients.  
30 Overall, 70.7% of patients attained normal resonance and 65.3% attained resolution of  
31 abnormal nasal emission following surgical intervention. There was no notable difference in  
32 speech outcomes, need for further surgery or occurrence of sleep disordered breathing across  
33 the categories of surgery examined. However, it was noted that outcomes were recorded  
34 using diverse parameters, particularly with regard to perceptual speech assessment, often  
35 with weak speech methodologies. This made comparison, even of well-defined cohort  
36 studies, problematic and meant that the clinical application potential of the review was  
37 limited.  
38  
39  
40  
41  
42

43 In this context, one might assume that randomized controlled trials comparing different types  
44 of VPD surgery would emerge as the preferred study design. However, there are practical  
45 difficulties in achieving this because of the relatively small numbers of patients with VPD,  
46 their heterogeneity and the existence of well-established protocols in individual units.  
47 Therefore comparative, cross-centre cohort studies are likely to continue to be important in  
48 research into VPD surgery. In order to usefully inform clinical decision-making, it is  
49 essential that the results of such studies can be compared in a standardized way.  
50  
51  
52  
53

54 One method to achieve this is to develop a core outcome set (COS). A core outcome set is a  
55 minimum set of outcomes that should be measured and reported in all studies in a specific  
56 field. Core outcome sets have been demonstrated to improve outcome reporting in healthcare  
57  
58  
59  
60



1  
2  
3  
4 trials.[30] It is important to note that a COS represents a minimum set of relevant outcomes  
5 that should be measured in a clinical study of a particular condition. The intent is not to limit  
6 researchers but rather to provide them with a minimum list of outcomes to include in their  
7 studies along with others of their choosing. There is a precedent for COS development in  
8 cleft care. The MOMENT study, published in 2015, developed a COS for the reporting of  
9 effectiveness trials for the management of otitis media with effusion (OME) in children with  
10 cleft palate.[31] A COS reflecting the opinions of clinicians and parents was developed,  
11 which included nine core outcomes that can be used in future trials of the management of  
12 OME in patients with clefts.  
13  
14  
15

### 16 17 **Objectives**

18 The aim of the current study is to develop a COS for consistent reporting of outcomes in  
19 studies of management of VPD. There is currently no available COS for studies of patients  
20 with VPD (<http://www.comet-initiative.org/studies/search>). Developing a COS would reduce  
21 outcome reporting bias and heterogeneity across studies of VPD. This would allow  
22 meaningful collation and comparison of results between different aetiologies, surgical  
23 protocols and institutions. Such an instrument would strengthen evidence for clinical  
24 decision making regarding intervention selection and would ultimately improve care for  
25 patients with VPD.  
26  
27  
28

29  
30 The objectives of the study are:

- 31 1. To compile a comprehensive list of clinical and patient-reported outcomes based on  
32 review of the published literature.
- 33 2. To group the listed outcomes in to predefined themes.
- 34 3. To achieve consensus on a minimum set of relevant outcomes for reporting studies of  
35 interventions for VPD.  
36  
37  
38

### 39 40 **Scope**

41 The scope of the study will include patients with both cleft and non-cleft VPD. The  
42 population will include both child and adult patients with VPD. Systematic review of the  
43 literature demonstrated an age range of 1-69 years for patients undergoing surgical treatment  
44 of VPD, [29] therefore no cut-off age limit will be applied. The COS will cover all surgical  
45 and non-surgical interventions for the management of VPD. It is anticipated that the COS  
46 could be applied in all future studies that examine outcomes of interventions for VPD.  
47  
48  
49  
50

### 51 52 **METHODS AND ANALYSIS**

53 The study will be carried out according to the guidance of the Core Outcome Measures in  
54 Effectiveness Trials (COMET) initiative.[32] The protocol for the study was developed in  
55 accordance with Core Outcome Set-STAndards for Development (COS-STAD)  
56 recommendations.[33] The protocol is presented using the Core Outcome Set-STANDARDISED  
57  
58  
59  
60



Protocol Items (COS-STAP) Statement for the content of a COS development study protocol.  
[34]

### Stakeholders

Stakeholder groups to be involved in the COS development process include patients or their representatives, cleft surgeons, cleft speech and language therapists and researchers with a demonstrated interest in VPD. Clinician stakeholder eligibility is based on involvement in the clinical care of children with VPD. Clinicians experienced in managing VPD will be identified by convenience sampling by members of the steering group and/or through their membership of relevant societies or organisations, (e.g. The Craniofacial Society of Great Britain and Ireland, The American Cleft Palate Association, Operation Smile). Furthermore, authors identified from the systematic review with a significant volume of publications in the field of VPD will be invited to participate.[29] Adult patient and parent participants will be recruited by convenience sampling by members of the steering group and through patient representative organisations.

### Steering group

A steering group will oversee the development of the core outcome set. The steering group consists of academic cleft surgeons (CdeB, REK, KCYS and DJAO) and speech and language therapists (AB and DS), an expert in COS development (SS) and the parent of a patient with VPD (HH). The steering group came together through the members' attendance at the First and Second International Symposium on VPD meetings, held at the Nationwide Children's Hospital in Columbus Ohio USA in 2016 and 2018. All members of the steering group will be co-authors of the COS.

### Public and patient involvement

The parent of a patient with VPD is included in the steering group of the study and in the authorship of this paper. Knowledge of the patient experience of VPD has been provided throughout the development of the protocol.

**Information sources** A systematic review of 83 papers, which presented results of surgery for VPD, has been published.[29] Outcomes recorded in papers included in this systematic review have been identified and recorded by the steering group. These outcomes have been presented and discussed at the Craniofacial Society of Great Britain and Ireland annual meeting (Birmingham UK 2018) and the Second International Symposium on VPD (Columbus Ohio USA 2018). Both of these meetings provided the opportunity to receive contributions from a wide range of multidisciplinary experts in the field through a series of focused workshops. Participants in these workshops were asked to review outcomes relevant to their clinical field and to comment on the suitability of inclusion of the outcome in the core outcome set. Based on this discussion, further outcomes were added to the initial list derived from the systematic review. This long list of outcomes will be reviewed

1  
2  
3  
4 independently by all members of the steering group. Duplicate outcomes will be removed. It  
5 is anticipated that certain outcomes may require separation in to sub-categories while others  
6 may be grouped together. This process will be undertaken independently by at least two  
7 members of the steering group, with expertise in the specific area (e.g. surgery, speech and  
8 language therapy). Resolution of conflicts will be carried out by the lead author. All  
9 outcomes will be reviewed and categorized independently by each member of the steering  
10 group into the following pre-specified themes: patient-reported outcomes; speech outcomes;  
11 nasal airway outcomes (including sleep-disordered breathing); surgical care outcomes.  
12  
13  
14  
15

### 16 **Consensus process**

17 A Delphi process will be carried out amongst international clinical cleft teams and their  
18 patients/parents to achieve consensus on the outcomes to be included in the COS. The Delphi  
19 process is a commonly used consensus technique,[35] which has frequently been used in  
20 COS development.[36-39] The Delphi process ensures that anonymous opinions can be  
21 obtained in a way that gives equal influence to all who participate, and avoids an individual  
22 participant being influenced by the opinions of any other participant.  
23  
24  
25

26 Plain language documents, which have been developed by the COMET initiative, will be  
27 used to explain COS development methodology to participants. The language of the  
28 outcomes themselves will be clarified and plain-language definitions will be added where  
29 necessary. The same version of the questionnaire will be used for both clinical and  
30 patient/parent participants. The questionnaire will be pilot tested to assess usability by  
31 members of staff and patient representatives in the departments of the steering group and  
32 modified accordingly.  
33  
34  
35  
36

37 There is no robust method for calculating the required sample size for a Delphi survey and  
38 assumptions are based on COMET Initiative guidelines and previous studies.[32] A balanced  
39 mix of stakeholders (adult patients, parents/guardians of patients, cleft surgeons, cleft speech  
40 and language therapists) will be identified by purposive sampling by the steering group,  
41 aiming for a total of 30 participants in the Delphi panel. While the steering group is made up  
42 of Irish, UK and USA participants, the aim is to include a wider international representation  
43 in the Delphi panel, including representation from low and middle-income countries. In  
44 keeping with previously described methodology, adult patient and parent participants will  
45 comprise 20% of the Delphi panel.[40]  
46  
47  
48  
49

50 Research Electronic Data Capture (REDCap) software will be used to deliver the Delphi  
51 survey to all participants.[41] Potential participants will be emailed full details of the study  
52 and asked for their consent to participate in the Delphi panel. Having completed an online  
53 consent form, they will then be invited to complete an online Delphi questionnaire. The  
54 panel will answer questionnaires in two rounds. After each round, the steering group will  
55 provide a de-identified summary of the panel's answers from the previous round. Thus,  
56  
57  
58  
59  
60

1  
2  
3  
4 participants are encouraged to revise their earlier answers in light of the responses of other  
5 members of their panel. Participants will be asked to complete each round of the Delphi  
6 exercise within three weeks of receipt of the email and will be reminded of this at the start of  
7 each survey. A reminder email will be sent at the end of week two to prompt completion of  
8 the survey. One further reminder will be sent to non-responders at the end of the three-week  
9 period.  
10  
11

12  
13 At the beginning of the first (Round 1) survey, participants will be presented with some plain  
14 language introductory information detailing the purpose and design of the study, as well as a  
15 glossary of terms. Round 1 content will comprise a long list of outcomes to be scored.  
16 Participants will also be provided with an option to add additional outcomes that they think  
17 are relevant. Any new outcomes identified by at least two Delphi participants will be  
18 included in Round 2 of the process.  
19  
20

### 21 22 **Consensus definition**

23 Consensus criteria will be specified a priori. Any outcome with a rating of 7 to 9 by 70% or  
24 more of the panel *and* 1 to 3 by 15% or fewer will be included in the COS. Any outcome  
25 with a rating of 1 to 3 by 70% or more of the panel *and* 7 to 9 by 15% or fewer will be  
26 excluded.[42] All other combinations indicated that no consensus had been achieved for the  
27 outcome. Round 2 may be analyzed using more stringent criteria if a higher proportion of  
28 outcomes than expected are rated critical. Specifically, a higher threshold of 75% or more of  
29 the panel rating 7 to 9 and 25% or fewer rating 1 to 3 will be applied. This decision will be  
30 based on the steering group's judgement and giving due consideration to current COMET  
31 recommendations regarding outcomes.[32] All items retained after two rounds of the Delphi  
32 survey will be included in the final core outcome set.  
33  
34  
35  
36  
37

### 38 **Outcomes scoring/feedback**

39 Participants will be asked to score each of the outcomes listed in Round 1 using the Grading  
40 of Recommendations, Assessment, Development and Evaluations (GRADE) scale of 1 to 9,  
41 with 1 to 3 labeled 'not important', 4 to 6 labeled 'important but not critical' and 7 to 9  
42 labeled 'critical'. [43] Round 1 responses will be analyzed according to the number of  
43 participants scoring each outcome within the GRADE criteria (1–3, 4–6, 7–9) for the  
44 purpose of group feedback in Round 2.  
45  
46  
47

48  
49 Round 2 will also be presented online and distributed via an electronic link embedded in an  
50 email. Round 2 will consist of all outcomes from Round 1 plus additional outcomes  
51 suggested by at least two Delphi participants in Round 1. In Round 2, participants will be  
52 shown their previous individual scores, together with group feedback (median score of group  
53 per item), and asked to reconsider their own scores in light of the group response when  
54 scoring outcomes in Round 2.  
55  
56  
57  
58  
59

### Missing data

The two main sources of missing data in a COS development consensus process are non-response (attrition) and partial response. As outlined above, two reminders will be sent to invited participants in order to maximize the response rate. To address non-response to Round 1, those who have not taken part in Round 1 will not be invited to participate in Round 2. To evaluate for attrition bias between rounds the following approach will be taken. For each survey item, the number of participants who have scored it and the distribution of scores will be summarised. The number of participants completing Round 2 will be documented and the potential for attrition bias will be assessed by comparing the participant scores for those who completed both rounds with those who completed Round 1 only. Changes in participant scores will be examined between rounds and the reasons given for these changes will be summarised.

### ETHICS AND DISSEMINATION

The study has ethical approval through Our Lady's Children's Hospital Crumlin Dublin Research and Ethics Committee, Ref: GEN/683/18. Informed consent will be obtained from all participants via an online form that can be completed at the start of the Round 1 Delphi survey. The study is registered with the Core Outcome Measures in Effectiveness Trials Initiative (<http://www.cometinitiative.org/studies/details/1146?result=true>).

The Core Outcome Set-STAndards for Reporting (COS-STAR) Equator Network guidelines will be used for the reporting of the COS.[44] All members of the steering group will coauthor the final paper, which will be submitted for peer-review and publication in a journal of interest to the multidisciplinary cleft palate community. In order to reach as wide an audience as possible, the core outcome set will also be submitted for presentation at a number of international meetings, including the Craniofacial Society of Great Britain and Ireland, the American Cleft Palate Association and the International Symposium on VPD. The core outcome set will be distributed to patients and parents via patient representative groups.

## REFERENCES

1. Kummer A. Resonance Disorders and Velopharyngeal Dysfunction (VPD). In: Kummer A, ed. *Cleft Palate and Craniofacial Anomalies: Effects on Speech and Resonance*. 3rd ed. NY, USA: Delamar 2014:182-224.
2. Bhuskute A, Skirko JR, Roth C, et al. Association of Velopharyngeal Insufficiency With Quality of Life and Patient-Reported Outcomes After Speech Surgery. *JAMA facial plastic surgery* 2017;19(5):406-12. doi: 10.1001/jamafacial.2017.0639 [published Online First: 2017/07/21]
3. Sell D, Grunwell P, Mildinhall S, et al. Cleft lip and palate care in the United Kingdom--the Clinical Standards Advisory Group (CSAG) Study. Part 3: speech outcomes. *Cleft Palate Craniofac J* 2001;38(1):30-7. doi: 10.1597/1545-1569\_2001\_038\_0030\_clapci\_2.0.co\_2
4. Cable BB, Canady JW, Karnell MP, et al. Pharyngeal flap surgery: long-term outcomes at the University of Iowa. *Plast Reconstr Surg* 2004;113(2):475-8. doi: 10.1097/01.PRS.0000100806.45065.35
5. Britton L, Albery L, Bowden M, et al. A cross-sectional cohort study of speech in five-year-olds with cleft palate +/- lip to support development of national audit standards: benchmarking speech standards in the United Kingdom. *Cleft Palate Craniofac J* 2014;51(4):431-51. doi: 10.1597/13-121
6. Hardy JC, Netsell R, Schweiger JW, et al. Management of velopharyngeal dysfunction in cerebral palsy. *The Journal of speech and hearing disorders* 1969;34(2):123-37. [published Online First: 1969/05/01]
7. Hillarp B, Ekberg O, Jacobsson S, et al. Myotonic dystrophy revealed at videoradiography of deglutition and speech in adult patients with velopharyngeal insufficiency: presentation of four cases. *Cleft Palate Craniofac J* 1994;31(2):125-33. doi: 10.1597/1545-1569(1994)031<0125:mdravo>2.3.co;2 [published Online First: 1994/03/01]
8. Horton SK, Murdoch BE, Theodoros DG, et al. Motor speech impairment in a case of childhood basilar artery stroke: treatment directions derived from physiological and perceptual assessment. *Pediatric rehabilitation* 1997;1(3):163-77. [published Online First: 1997/07/01]
9. Huang MH, Lee ST, Rajendran K. Anatomic basis of cleft palate and velopharyngeal surgery: implications from a fresh cadaveric study. *Plast Reconstr Surg* 1998;101(3):613-27; discussion 28-9. [published Online First: 1998/03/21]
10. Sommerlad BC, Mehendale FV, Birch MJ, et al. Palate re-repair revisited. *Cleft Palate Craniofac J* 2002;39(3):295-307. doi: 10.1597/1545-1569(2002)039<0295:prrr>2.0.co;2 [published Online First: 2002/05/23]
11. Furlow LT, Jr. Cleft palate repair by double opposing Z-plasty. *Plast Reconstr Surg* 1986;78(6):724-38. [published Online First: 1986/12/01]
12. Hudson DA, Grobbelaar AO, Fernandes DB, et al. Treatment of velopharyngeal incompetence by the Furlow Z-plasty. *Ann Plast Surg* 1995;34(1):23-6. [published Online First: 1995/01/01]
13. Chen PKT, Wu JTH, Chen YR, et al. Correction of secondary velopharyngeal insufficiency in cleft palate patients with the Furlow palatoplasty. *Plast Reconstr Surg* 1994;94(7):933-43.



14. Chen PK, Wu JT, Chen YR, et al. Correction of secondary velopharyngeal insufficiency in cleft palate patients with the Furlow palatoplasty. *Plast Reconstr Surg* 1994;94(7):933-41; discussion 42-3.
15. Hill C, Hayden C, Riaz M, et al. Buccinator sandwich pushback: A new technique for treatment of secondary velopharyngeal incompetence. *The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association* 2004;41(3):230-37.
16. Mann RJ, Neaman KC, Armstrong SD, et al. The double-opposing buccal flap procedure for palatal lengthening. *Plast Reconstr Surg* 2011;127(6):2413-18.
17. Hens G, Sell D, Pinkstone M, et al. Palate lengthening by buccinator myomucosal flaps for velopharyngeal insufficiency. *Cleft Palate Craniofac J* 2013;50(5):e84-91. doi: 10.1597/11-211
18. Hynes W. Pharyngoplasty by muscle transplantation. *Br J Plast Surg* 1950;3(2):128-35.
19. Orticochea M. A review of 236 cleft palate patients treated with dynamic muscle sphincter. *Plast Reconstr Surg* 1983;71(2):180-8. [published Online First: 1983/02/01]
20. Jackson IT. Sphincter pharyngoplasty. *Clin Plast Surg* 1985;12(4):711-7. [published Online First: 1985/10/01]
21. Sloan GM. Posterior pharyngeal flap and sphincter pharyngoplasty: the state of the art. *Cleft Palate Craniofac J* 2000;37(2):112-22. doi: 10.1597/1545-1569(2000)037<0112:PPFASP>2.3.CO;2
22. Filip C, Matzen M, Aagaens I, et al. Autologous fat transplantation to the velopharynx for treating persistent velopharyngeal insufficiency of mild degree secondary to overt or submucous cleft palate. *J Plast Reconstr Aesthet Surg* 2013;66(3):337-44. doi: 10.1016/j.bjps.2012.11.006
23. Gray SD, Pinborough-zimmerman J, Catten M. Posterior wall augmentation for treatment of velopharyngeal insufficiency. *Otolaryngol Head Neck Surg* 1999;121(1):107-12. doi: 10.1016/s0194-5998(99)70135-x [published Online First: 1999/07/02]
24. Skoog T. The Pharyngeal Flap Operation in Cleft Palate. A Clinical Study of Eighty-Two Cases. *Br J Plast Surg* 1965;18:265-82.
25. Honig CA. The treatment of velopharyngeal insufficiency after palatal repair. *Arch Chir Neerlandicum* 1967;19(1):71-81.
26. Honig CA. The treatment of velopharyngeal insufficiency after palatal repair. *Arch Chir Neerl* 1967;19(1):71-81. [published Online First: 1967/01/01]
27. Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. *Annals of surgery* 1998;228(4):491-507. [published Online First: 1998/10/28]
28. Marang-van de Mheen PJ, Stadlander MC, Kievit J. Adverse outcomes in surgical patients: implementation of a nationwide reporting system. *Qual Saf Health Care* 2006;15(5):320-4. doi: 10.1136/qshc.2005.016220 [published Online First: 2006/11/01]
29. de Blacam C, Smith S, Orr D. Surgery for Velopharyngeal Dysfunction: A Systematic Review of Interventions and Outcomes. *Cleft Palate Craniofac J* 2018;55(3):405-22. doi: 10.1177/1055665617735102

30. Kirkham JJ, Boers M, Tugwell P, et al. Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. *Trials* 2013;14:324. doi: 10.1186/1745-6215-14-324 [published Online First: 2013/10/10]
31. Bruce I, Harman N, Williamson P, et al. The management of Otitis Media with Effusion in children with cleft palate (mOMent): a feasibility study and economic evaluation. *Health Technol Assess* 2015;19(68):1-374. doi: 10.3310/hta19680
32. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. *Trials* 2017;18(Suppl 3):280. doi: 10.1186/s13063-017-1978-4
33. Kirkham JJ, Davis K, Altman DG, et al. Core Outcome Set-STAndards for Development: The COS-STAD recommendations. *PLoS Med* 2017;14(11):e1002447. doi: 10.1371/journal.pmed.1002447 [published Online First: 2017/11/18]
34. Kirkham JJ, Gorst S, Altman DG, et al. Core Outcome Set-STANDARDISED Protocol Items: the COS-STAP Statement.
35. Brown BB. Delphi Process: A Methodology Used for the Elicitation of Opinions of Experts. Santa Monica, CA: RAND Corporation 1968.
36. Prinsen CA, Vohra S, Rose MR, et al. Core Outcome Measures in Effectiveness Trials (COMET) initiative: protocol for an international Delphi study to achieve consensus on how to select outcome measurement instruments for outcomes included in a 'core outcome set'. *Trials* 2014;15:247. doi: 10.1186/1745-6215-15-247 [published Online First: 2014/06/26]
37. Iyengar S, Williamson PR, Schmitt J, et al. Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials* 2016;17(1):429. doi: 10.1186/s13063-016-1554-3 [published Online First: 2016/09/02]
38. Harman NL, Bruce IA, Callery P, et al. MOMENT--Management of Otitis Media with Effusion in Cleft Palate: protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. *Trials* 2013;14:70. doi: 10.1186/1745-6215-14-70 [published Online First: 2013/03/19]
39. Young A, Brookes S, Rumsey N, et al. Agreement on what to measure in randomised controlled trials in burn care: study protocol for the development of a core outcome set. *BMJ Open* 2017;7(6):e017267. doi: 10.1136/bmjopen-2017-017267 [published Online First: 2017/07/04]
40. Smith SM, Wallace E, Salisbury C, et al. A Core Outcome Set for Multimorbidity Research (COSmm). *Annals of family medicine* 2018;16(2):132-38. doi: 10.1370/afm.2178 [published Online First: 2018/03/14]
41. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010 [published Online First: 2008/10/22]
42. Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials* 2012;13:132. doi: 10.1186/1745-6215-13-132
43. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011;64(4):395-400. doi: 10.1016/j.jclinepi.2010.09.012
44. Kirkham JJ, Gorst S, Altman DG, et al. Core Outcome Set-STAndards for Reporting: The COS-STAR Statement. *PLoS Med* 2016;13(10):e1002148. doi: 10.1371/journal.pmed.1002148

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## CONTRIBUTORS

CdeB wrote the paper and conceived the project with the support of DJAO. HH contributed knowledge of the patient experience of VPD. SS contributed knowledge of core outcome set development. AB and DS contributed knowledge of speech and language therapy. REK, DJAO and KCYS contributed knowledge of VPD surgery and airway. All authors edited and critically revised the study protocol. All authors have read, contributed to and approved the manuscript.

## FUNDING STATEMENT

This study has not received any funding.

## COMPETING INTERESTS STATEMENT

The authors have no competing interests to declare.

## ETHICS APPROVAL

Our Lady's Children's Hospital Crumlin Dublin Research and Ethics Committee, Ref: GEN/683/18

## WORD COUNT

3,471 words

Item			Included, page
TITLE/ABSTRACT			
Title	1a	Identify in the title that the paper describes the protocol for the planned development of a COS	Yes, 1
Abstract	1b	Provide a structured abstract	Yes, 2
INTRODUCTION			
Background and objectives	2a	Describe the background and explain the rationale for developing the COS, and identify the reasons why a COS is needed and the potential barriers to its implementation	Yes, 4-6
	2b	Describe the specific objectives with reference to developing a COS	Yes, 6
Scope	3a	Describe the health condition(s) and population(s) that will be covered by the COS	Yes, 6
	3b	Describe the intervention(s) that will be covered by the COS	Yes, 6
	3c	Describe the context of use for which the COS is to be applied	Yes, 6
METHODS			
Stakeholders	4	Describe the stakeholder groups to be involved in the COS development process, the nature of and rationale for their involvement and also how the individuals will be identified; this should cover involvement both as members of the research team and as participants in the study	Yes, 7
Information sources	5a	Describe the information sources that will be used to identify the list of outcomes. Outline the methods or reference other protocols/papers	Yes, 7-8
	5b	Describe how outcomes may be dropped/combined, with reasons	Yes, 8
Consensus process	6	Describe the plans for how the consensus process will be undertaken	Yes, 8
Consensus definition	7a	Describe the consensus definition	Yes, 9
	7b	Describe the procedure for determining how outcomes will be added/combined/dropped from consideration during the consensus process	Yes, 8
ANALYSIS			
Outcome scoring/feedback	8	Describe how outcomes will be scored and summarised, describe how participants will receive feedback during the consensus process	Yes, 9
Missing data	9	Describe how missing data will be handled during the consensus process	Yes, 10
ETHICS and DISSEMINATION			

Ethics approval/informed consent	10	Describe any plans for obtaining research ethics committee/institutional review board approval in relation to the consensus process and describe how informed consent will be obtained (if relevant)	Yes, 10
Dissemination	11	Describe any plans to communicate the results to study participants and COS users, inclusive of methods and timing of dissemination	Yes, 10
ADMINISTRATIVE INFORMATION			
Funders	12	Describe sources of funding, role of funders	Yes, 15
Conflicts of interest	13	Describe any potential conflicts of interest within the study team and how they will be managed	Yes, 15

**COS-STAP  
Checklist**

For peer review only